Stock Events

Stock Events

Search...

Argent Biopharma

A$0.33

58

+A$0+0% Friday 06:10

Statistics

Day High

0.34

Day Low

0.32

52W High

0.45

52W Low

0.15

Volume

4,240

Avg. Volume

59,351

Mkt Cap

14.76M

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

30AugExpected

Q4 2023

Next

-20.86

-20.53

-20.19

-19.86

Expected EPS

N/A

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RGT.AU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Pfizer is a global pharmaceutical company that competes in various therapeutic areas, including those Argent Biopharma is involved in.

Merck operates in similar therapeutic areas as Argent Biopharma, making them direct competitors in the pharmaceutical industry.

Johnson & Johnson

Johnson & Johnson, through its pharmaceutical division Janssen, competes with Argent Biopharma in developing treatments for various diseases.

AbbVie competes in the biopharmaceutical field, focusing on areas like immunology and oncology, which may overlap with Argent Biopharma's interests.

Amgen is a biotechnology company that develops innovative therapeutics, potentially in competition with Argent Biopharma's product pipeline.

Bristol-Myers Squibb

Bristol Myers Squibb is involved in discovering, developing, and delivering innovative medicines that could compete with Argent Biopharma's offerings.

Gilead Sciences

Gilead Sciences is a biopharmaceutical company that focuses on areas such as infectious diseases, where Argent Biopharma may also be active.

Novartis is a global healthcare company that operates in various therapeutic areas, potentially competing with Argent Biopharma.

Roche Holding AG, through its pharmaceuticals and diagnostics divisions, competes in the development of innovative healthcare solutions.

Sanofi is a global biopharmaceutical company focusing on human health, directly competing with Argent Biopharma in several therapeutic areas.

About

Argent BioPharma Limited, a drug discovery clinical-stage biopharmaceutical company, provides medicines targeting immunology and neurology worldwide. Its principal product candidates include CimetrA, which is in phase II clinical trial for the treatment of SLE Lupus, anti-inflammatory, and SARS COVID-19; and CannEpil, which is in phase I clinical trial for refractory epilepsy and cerebral palsy; and CogniCann, which is in phase I clinical trial for the symptomatic relief of Dementia and Alzheimer. In addition, the company provides Irnican for brain cancer. The company was formerly known as MGC Pharmaceuticals Limited and changed it name to Argent BioPharma Limited. Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.

Show more...

CEO

Mr. Roby Reuven Zomer

Country

AU

ISIN

AU0000326647

Listings